InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of the complement system for application in threatening inflammatory diseases and certain orhan drug indications. Its pipeline products includes IFX-1 and IFX-2. InflaRx operates in various research and development programs in life science sectors. The company offers antibodies that are able to fulfil requirements determined by InflaRx for generation of suitable drug candidates. It offers research services through collaboration with universities and biotech companies. InflaRx is headquartered in Jena, Germany.

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
InflaRx NV, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
InflaRx Raises USD55 Million in Series D Financing 10
InflaRx Raises USD34 Million in Series C Venture Financing 11
InflaRx Raises Funds through Series B Financing Round 12
Partnerships 13
InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13
Equity Offering 14
InflaRx Raises USD117.3 Million in Public Offering of Shares 14
InflaRx Raises USD100 Million in IPO 16
InflaRx NV - Key Competitors 17
InflaRx NV - Key Employees 18
InflaRx NV - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Aug 09, 2018: InflaRx reports second quarter 2018 financial & operating results 20
May 17, 2018: InflaRx Reports First Quarter 2018 Financial & Operating Results 21
Mar 29, 2018: InflaRx Full Year 2017 Financial & Operating Results 23
Corporate Communications 24
Feb 06, 2018: InflaRx Names Tony Gibney As Board Director 24
Jun 21, 2017: InflaRx Promotes Othmar Zenker, M.D. to Newly Created Position of Chief Medical Officer 25
Clinical Trials 26
Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa 26
Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa 27
Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa 28
Jan 04, 2017: InflaRx initiates exploratory phase II trial with IFX-1, a first-in-class anti-complement C5a antibody, in patients with Hidradenitis Suppurativa 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List Of Tables


InflaRx NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Deals By Therapy Area, 2012 to YTD 2018 8
InflaRx NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
InflaRx Raises USD55 Million in Series D Financing 10
InflaRx Raises USD34 Million in Series C Venture Financing 11
InflaRx Raises Funds through Series B Financing Round 12
InflaRx Enters into Co-Development Agreement with Beijing Defengrei Biotechnology 13
InflaRx Raises USD117.3 Million in Public Offering of Shares 14
InflaRx Raises USD100 Million in IPO 16
InflaRx NV, Key Competitors 17
InflaRx NV, Key Employees 18
InflaRx NV, Other Locations 19

List Of Figures


InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
InflaRx NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
InflaRx NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

InflaRx NV (IFRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of

USD 250 View Report

InflaRx NV (IFRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of

USD 250 View Report

InflaRx NV (IFRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

InflaRx NV (InflaRx) is a clinical-stage biopharmaceutical company that develops therapies in the field of acute and chronic inflammation. The company offers development of monoclonal antibodies targeting activation products of

USD 250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available